Research programme: neurodegenerative disease therapeutics - IXICO
Alternative Names: PYM 60086Latest Information Update: 16 Jul 2016
At a glance
- Originator Phytopharm
- Developer IXICO
- Class Spirostans
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders; Dementia; Memory disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dementia in United Kingdom (PO)